Cormedix Stock Book Value Per Share
| CRMD Stock | USD 9.96 0.37 3.58% |
CorMedix fundamentals help investors to digest information that contributes to CorMedix's financial success or failures. It also enables traders to predict the movement of CorMedix Stock. The fundamental analysis module provides a way to measure CorMedix's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CorMedix stock.
| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.38 | 1.45 | |
| Tangible Book Value Per Share | 1.38 | 1.45 |
CorMedix | Book Value Per Share |
CorMedix Company Book Value Per Share Analysis
CorMedix's Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current CorMedix Book Value Per Share | 1.01 X |
Most of CorMedix's fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CorMedix is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
CorMedix Book Value Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for CorMedix is extremely important. It helps to project a fair market value of CorMedix Stock properly, considering its historical fundamentals such as Book Value Per Share. Since CorMedix's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of CorMedix's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of CorMedix's interrelated accounts and indicators.
Click cells to compare fundamentals
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
| Competition |
CorMedix Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
In accordance with the recently published financial statements, the book value per share of CorMedix is about 1.014 times. This is 159.65% lower than that of the Pharmaceuticals sector and 100.41% lower than that of the Health Care industry. The book value per share for all United States stocks is 99.95% higher than that of the company.
CorMedix Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CorMedix's direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CorMedix could also be used in its relative valuation, which is a method of valuing CorMedix by comparing valuation metrics of similar companies.CorMedix is currently under evaluation in book value per share category among its peers.
CorMedix Current Valuation Drivers
We derive many important indicators used in calculating different scores of CorMedix from analyzing CorMedix's financial statements. These drivers represent accounts that assess CorMedix's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of CorMedix's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 175.8M | 212.2M | 171.1M | 169.4M | 191.4M | 201.0M | |
| Enterprise Value | 159.3M | 171.2M | 118.5M | 126.8M | 148.4M | 155.8M |
CorMedix ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, CorMedix's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to CorMedix's managers, analysts, and investors.Environmental | Governance | Social |
CorMedix Fundamentals
| Return On Equity | -0.65 | ||||
| Return On Asset | -0.38 | ||||
| Operating Margin | (0.29) % | ||||
| Current Valuation | 558.87 M | ||||
| Shares Outstanding | 60.68 M | ||||
| Shares Owned By Insiders | 0.97 % | ||||
| Shares Owned By Institutions | 31.64 % | ||||
| Number Of Shares Shorted | 6.28 M | ||||
| Price To Earning | (0.88) X | ||||
| Price To Book | 10.29 X | ||||
| Price To Sales | 49.29 X | ||||
| Gross Profit | 61.67 K | ||||
| EBITDA | (48.89 M) | ||||
| Net Income | (46.34 M) | ||||
| Cash And Equivalents | 64.62 M | ||||
| Cash Per Share | 1.57 X | ||||
| Total Debt | 667.63 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 12.40 X | ||||
| Book Value Per Share | 1.01 X | ||||
| Cash Flow From Operations | (38.41 M) | ||||
| Short Ratio | 4.53 X | ||||
| Earnings Per Share | (0.80) X | ||||
| Target Price | 14.25 | ||||
| Number Of Employees | 82 | ||||
| Beta | 1.58 | ||||
| Market Capitalization | 604.34 M | ||||
| Total Asset | 82.06 M | ||||
| Retained Earnings | (321.7 M) | ||||
| Working Capital | 68.05 M | ||||
| Current Asset | 37.06 M | ||||
| Current Liabilities | 3.06 M | ||||
| Net Asset | 82.06 M |
About CorMedix Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CorMedix's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CorMedix using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CorMedix based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether CorMedix is a strong investment it is important to analyze CorMedix's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CorMedix's future performance. For an informed investment choice regarding CorMedix Stock, refer to the following important reports:Check out CorMedix Piotroski F Score and CorMedix Altman Z Score analysis. For information on how to trade CorMedix Stock refer to our How to Trade CorMedix Stock guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CorMedix. If investors know CorMedix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CorMedix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.80) | Revenue Per Share 0.212 | Quarterly Revenue Growth (0.47) | Return On Assets (0.38) | Return On Equity (0.65) |
The market value of CorMedix is measured differently than its book value, which is the value of CorMedix that is recorded on the company's balance sheet. Investors also form their own opinion of CorMedix's value that differs from its market value or its book value, called intrinsic value, which is CorMedix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CorMedix's market value can be influenced by many factors that don't directly affect CorMedix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CorMedix's value and its price as these two are different measures arrived at by different means. Investors typically determine if CorMedix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CorMedix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.